A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-γ signaling in lupus-affected (NZB × NZW)F1 mice

Clinical Immunology

Volumn 133, Issue 1, 2009, Pages 61-68

  Sharabi, Amir ^a   Sthoeger, Zev M ^b   Mahlab, Keren ^a,b   Lapter, Smadar ^a   Zinger, Heidy ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN HOSPITAL   (Israel)

Author keywords

Autoimmune diseases; Cytokine; IFN signaling pathway; Peptide based therapy; Signal transduction and activators of transcription 1 (STAT1); Suppressor of cytokine signaling 1 (SOCS 1); Systemic lupus erythematosus (SLE); T cells

Indexed keywords

GAMMA INTERFERON; GLYCYLTYROSYLTYROSYLTRYPTOPHYLSERYLTRYPTOPHYLISOLEUCYLARGINYL GLUTAMINYLPROLYLPROLYLGLYCYLLYSYLGLYCYLGLUTAMYLGLUTAMYLTRYPTOPHYL ISOLEUCYLGLYCINE; HCDR1 PROTEIN; PEPTIDE; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; AUTOANTIGENS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INTERFERON-GAMMA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; NERVE TISSUE PROTEINS; PEPTIDES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UP-REGULATION;

EID: 69949180748     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.06.010     Document Type: Article

References (40)

1. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., and Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301 (1979) 5-8
2. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2610-2615
3. Segal R., Bermas B.L., Dayan M., Kalush F., Shearer G.M., and Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J. Immunol. 158 (1997) 3009-3016
4. Baccala R., Kono D.H., and Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol. Rev. 204 (2005) 9-26
5. Jacob C.O., van der Meide P.H., and McDevitt H.O. In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med. 166 (1987) 798-803
6. Seery J.P., Carroll J.M., Cattell V., and Watt F.M. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J. Exp. Med. 186 (1997) 1451-1459
7. Haas C., Ryffel B., and Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW)F1 mice. J. Immunol. 160 (1998) 3713-3718
8. Ozmen L., Roman D., Fountoulakis M., Schmid G., Ryffel B., and Garotta G. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25 (1995) 6-12
9. Darnell J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
10. Ihle J.N. Cytokine receptor signalling. Nature 377 (1995) 591-594
11. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., et al. A family of cytokine-inducible inhibitors of signaling. Nature 387 (1997) 917-921
12. Naka T., Matsumoto T., Narazaki M., Fujimoto M., Morita Y., Ohsawa Y., Saito H., Nagasawa T., Uchiyama Y., and Kishimoto T. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15577-15582
13. Marine J.C., Topham D.J., McKay C., Wang D., Parganas E., Stravopodis D., Yoshimura A., and Ihle J.N. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98 (1999) 609-616
14. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98 (1999) 597-608
15. Hanada T., Yoshida H., Kato S., Tanaka K., Masutani K., Tsukada J., Nomura Y., Mimata H., Kubo M., and Yoshimura A. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19 (2003) 437-450
16. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., Elkayam O., and Mozes E. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin. Exp. Immunol. 131 (2003) 385-392
17. Waisman A., Shoenfeld Y., Blank M., Ruiz P.J., and Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int. Immunol. 7 (1995) 689-696
18. Luger D., Dayan M., Zinger H., Liu J.P., and Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24 (2004) 579-590
19. Sharabi A., Zinger H., Zborowsky M., Sthoeger Z.M., and Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8810-8815
20. Sharabi A., Azulai H., Sthoeger Z.M., and Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121 (2007) 248-257
21. Sharabi A., and Mozes E. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J. Immunol. 181 (2008) 3243-3251
22. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., and Mozes E. Amelioration of SLE-like manifestations in (NZB × NZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin. Immunol. 117 (2005) 262-270
23. Sharabi A., Haviv A., Zinger H., Dayan M., and Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin. Immunol. 119 (2006) 146-155
24. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., and Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol. 179 (2007) 4979-4987
25. Parameswaran R., Ben-David H., Sharabi A., Zinger H., and Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin. Immunol. 131 (2009) 223-232
26. Ben-David H., Sharabi A., Parameswaran R., Zinger H., and Mozes E. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of IL-7, leading to apoptosis. Immunology (2009) 10.1111/j.1365-2567.2009.03109.x
27. Sela U., Sharabi A., Dayan M., Hershkoviz R., and Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology (2008) 10.1111/j.1365-2567.2008.02988.x
28. Sela U., Dayan M., Hershkoviz R., Cahalon L., Lider O., and Mozes E. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur. J. Immunol. 36 (2006) 2971-2980
29. Sela U., Dayan M., Hershkoviz R., Lider O., and Mozes E. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3. J. Immunol. 180 (2008) 1584-1591
30. Karonitsch T., Feierl E., Steiner C.W., Dalwigk K., Korb A., Binder N., Rapp A., Steiner G., Scheinecker C., Smolen J., and Aringer M. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum. 60 (2009) 1463-1471
31. Peeva E., Michael D., Cleary J., Rice J., Chen X., and Diamond B. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 111 (2003) 275-283
32. Lindeman G.J., Wittlin S., Lada H., Naylor M.J., Santamaria M., Zhang J.G., Starr R., Hilton D.J., Alexander W.S., Ormandy C.J., and Visvader J. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev. 15 (2001) 1631-1636
33. Narazaki M., Fujimoto M., Matsumoto T., Morita Y., Saito H., Kajita T., Yoshizaki K., Naka T., and Kishimoto T. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13130-13134
34. Zhang J.G., Farley A., Nicholson S.E., Willson T.A., Zugaro L.M., Simpson R.J., Moritz R.L., Cary D., Richardson R., Hausmann G., Kile B.J., Kent S.B., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A., and Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2071-2076
35. Naka T., Tsutsui H., Fujimoto M., Kawazoe Y., Kohzaki H., Morita Y., Nakagawa R., Narazaki M., Adachi K., Yoshimoto T., Nakanishi K., and Kishimoto T. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity 14 (2001) 535-545
36. Catlett I.M., and Hedrick S.M. Suppressor of cytokine signaling 1 is required for the differentiation of CD4+ T cells. Nat. Immunol. 6 (2005) 715-721
37. Hanada T., Tanaka K., Matsumura Y., Yamauchi M., Nishinakamura H., Aburatani H., Mashima R., Kubo M., Kobayashi T., and Yoshimura A. Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J. Immunol. 174 (2005) 4325-4332
38. Evel-Kabler K., Song X.T., Aldrich M., Huang X.F., and Chen S.Y. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116 (2006) 90-100
39. Egan P.J., Lawlor K.E., Alexander W.S., and Wicks I.P. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J. Clin. Invest. 111 (2003) 915-924
40. Mujtaba M.G., Flowers L.O., Patel C.B., Patel R.A., Haider M.I., and Johnson H.M. Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J. Immunol. 175 (2005) 5077-5086